Françoise Farace

4.8k total citations
93 papers, 3.3k citations indexed

About

Françoise Farace is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Françoise Farace has authored 93 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Oncology, 50 papers in Cancer Research and 32 papers in Molecular Biology. Recurrent topics in Françoise Farace's work include Cancer Genomics and Diagnostics (33 papers), Cancer Cells and Metastasis (29 papers) and Lung Cancer Treatments and Mutations (18 papers). Françoise Farace is often cited by papers focused on Cancer Genomics and Diagnostics (33 papers), Cancer Cells and Metastasis (29 papers) and Lung Cancer Treatments and Mutations (18 papers). Françoise Farace collaborates with scholars based in France, United States and Italy. Françoise Farace's co-authors include Philippe Vielh, David Planchard, Jean‐Charles Soria, Marianne Oulhen, Benjamin Besse, Pablo Ernesto Pérez, Emma Pailler, Thomas Tursz, Hanne Gahéry‐Ségard and Mélissa Taylor and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Françoise Farace

89 papers receiving 3.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Françoise Farace France	31	1.9k	1.2k	1.1k	843	478	93	3.3k
Jaco Kraan Netherlands	36	1.6k 0.8×	1.2k 1.0×	1.1k 1.0×	832 1.0×	306 0.6×	112	3.5k
Erica L. Carpenter United States	26	1.1k 0.6×	1.1k 0.9×	1.4k 1.3×	620 0.7×	374 0.8×	100	3.0k
André Pèlegrin France	38	1.5k 0.8×	397 0.3×	1.6k 1.5×	979 1.2×	651 1.4×	148	4.4k
Vincent L. Morris Canada	25	1.5k 0.8×	833 0.7×	1.3k 1.2×	331 0.4×	286 0.6×	44	3.1k
Jerald J. Killion United States	25	1.2k 0.6×	708 0.6×	1.5k 1.4×	702 0.8×	220 0.5×	68	3.1k
Laurence Desjardins France	39	1.7k 0.9×	454 0.4×	1.3k 1.2×	869 1.0×	196 0.4×	188	5.0k
Kim Monkhorst Netherlands	28	1.8k 0.9×	665 0.6×	986 0.9×	1.5k 1.8×	183 0.4×	112	3.4k
Christina S. Kong United States	35	1.6k 0.8×	731 0.6×	1.3k 1.2×	737 0.9×	219 0.5×	124	4.3k
Olivier Gires Germany	42	3.4k 1.8×	1.3k 1.1×	2.8k 2.6×	496 0.6×	448 0.9×	109	6.2k
Larry E. Morrison United States	28	1.7k 0.9×	1.1k 1.0×	1.6k 1.5×	526 0.6×	330 0.7×	64	3.7k

Countries citing papers authored by Françoise Farace

Since Specialization

Citations

This map shows the geographic impact of Françoise Farace's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Françoise Farace with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Françoise Farace more than expected).

Fields of papers citing papers by Françoise Farace

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Françoise Farace. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Françoise Farace. The network helps show where Françoise Farace may publish in the future.

Co-authorship network of co-authors of Françoise Farace

This figure shows the co-authorship network connecting the top 25 collaborators of Françoise Farace. A scholar is included among the top collaborators of Françoise Farace based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Françoise Farace. Françoise Farace is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mezquita, Laura, Marianne Oulhen, Marc Deloger, et al.. (2024). Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer. British Journal of Cancer. 130(4). 682–693. 1 indexed citations

Faugeroux, Vincent, Marianne Oulhen, Olivier Déas, et al.. (2022). Targeting genome integrity dysfunctions impedes metastatic potency in non–small cell lung cancer circulating tumor cell–derived explants. JCI Insight. 7(11). 10 indexed citations

Oulhen, Marianne, Patrycja Pawlikowska, Genny Buson, et al.. (2021). Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. npj Precision Oncology. 5(1). 67–67. 17 indexed citations

Pawlikowska, Patrycja, Marianne Oulhen, Vincent Faugeroux, et al.. (2020). Exploitation of the chick embryo chorioallantoic membrane (CAM) as a platform for anti-metastatic drug testing. Scientific Reports. 10(1). 16876–16876. 46 indexed citations

Pailler, Emma, Vincent Faugeroux, Marianne Oulhen, et al.. (2019). Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK -Rearranged Non–Small-Cell Lung Cancer. Clinical Cancer Research. 25(22). 6671–6682. 92 indexed citations

Pailler, Emma, Marianne Oulhen, Isabelle Borget, et al.. (2017). Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK -Rearranged Non–Small Cell Lung Cancer Patients. Cancer Research. 77(9). 2222–2230. 59 indexed citations

Massard, Christophe, Isabelle Borget, Françoise Farace, et al.. (2017). RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study. European Journal of Cancer. 83. 185–193. 18 indexed citations

Facchinetti, Francesco, Yohann Loriot, Mei-Shiue Kuo, et al.. (2016). Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1 - and ALK -Rearranged Lung Cancers. Clinical Cancer Research. 22(24). 5983–5991. 111 indexed citations

Bahleda, Rastislav, Antoine Hollebecque, Andréa Varga, et al.. (2015). Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours. British Journal of Cancer. 113(10). 1413–1420. 16 indexed citations

10.

Mitry, Emmanuel, Thomas Walter, Éric Baudin, et al.. (2014). Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial) – A phase II non-randomised trial. European Journal of Cancer. 50(18). 3107–3115. 73 indexed citations

11.

Sessa, Cristiana, Patricia LoRusso, Anthony W. Tolcher, et al.. (2013). Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors. Clinical Cancer Research. 19(17). 4832–4842. 42 indexed citations

12.

Taylor, Mélissa, Fanny Billiot, Virginie Marty, et al.. (2012). Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells. Cancer Discovery. 2(5). 434–449. 37 indexed citations

13.

Arnedos, Mónica, Fabrice André, Françoise Farace, et al.. (2012). The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: The case of the Institut Gustave Roussy. Molecular Oncology. 6(2). 204–210. 13 indexed citations

14.

Bonvalot, Sylvie, Thierry de Baère, Jean Mendiboure, et al.. (2012). Hyperthermic Pelvic Perfusion With Tumor Necrosis Factor-α for Locally Advanced Cancers. Annals of Surgery. 255(2). 281–286. 18 indexed citations

15.

Jacques, Nathalie, Nadège Vimond, Rosa Conforti, et al.. (2008). Quantification of circulating mature endothelial cells using a whole blood four-color flow cytometric assay. Journal of Immunological Methods. 337(2). 132–143. 40 indexed citations

16.

Rubino, Corrado, et al.. (2004). Treatment of non-melanoma skin cancer in North Sardinia: is there a need for biopsy?. PubMed. 46(4). 110–4. 4 indexed citations

17.

Farace, Françoise, Laetitia Prestoz, Martine Guillier, et al.. (2004). Evaluation of Hematopoietic Potential Generated by Transplantation of Muscle-Derived Stem Cells in Mice. Stem Cells and Development. 13(1). 83–92. 7 indexed citations

18.

Gal, Frédérique‐Anne Le, Armelle Prévost‐Blondel, Renée Lengagne, et al.. (2001). Lipopeptide‐based melanoma cancer vaccine induced a strong MART‐27‐35‐cytotoxic T lymphocyte response in a preclinal study. International Journal of Cancer. 98(2). 221–227. 29 indexed citations

19.

Savelieva, Elena, Françoise Farace, Eric Angevin, et al.. (1994). T-Cell Receptor Repertoire in Colorectal Adenocarcinoma Patients with Hepatic Metastases and Its Changes Induced by Preoperative Adjuvant Interleukin-2 Therapy. Journal of Immunotherapy. 16(1). 66–76. 7 indexed citations

20.

Farace, Françoise, et al.. (1994). The decreased expression of CD3 ζ chains in cancer patients is not reversed BY IL‐2 Administration. International Journal of Cancer. 59(6). 752–755. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact